Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1 SAD of Efpegerglucagon in Healthy Subjects
NCT04032782Phase 1Completed
- Sponsor
- Hanmi Pharmaceutical
- Start
- Oct 2018
- Primary completion
- Aug 2019
- Modality
- Peptides
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in congenital hyperinsulinism (HI) comparing HM15136 with Placebo (2 arms). Primary endpoint: Adverse Event at Day 30. Started Oct 2018; status: completed.
02
Drugs
efpegerglucagon
03
Conditions
congenital hyperinsulinism (HI)
Beyond the preview
Go deeper on NCT04032782.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04032782.